Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...